Therefore, we sought to investigate the anticancer effects of the novel FOXM1 inhibitor, STL001 in a variety of human cancers from solid tumors including ovarian, colorectal, breast, esophageal, and prostate cancers. This evidence concerns the gene FOXM1 and Familial prostate cancer.